New Rhein Healthcare Investors, Andera Partners and Omega Funds led a $160m Series A round in Alveus Therapeutics.

New Rhein Healthcare Investors, a private equity firm, Andera Partners, an asset management firm, and Omega Funds, an international investment firm, led a $160m Series A round in Alveus Therapeutics, a clinical-stage biotechnology company developing next-generation therapies for obesity and metabolic diseases, with a participation from Sanofi Capital, Kurma Partners and Avego BioScience Capital. Proceeds from the financing will support Phase 2 clinical development of ALV-100, the company’s lead program, and Investigational New Drug (IND) filings of several early proprietary development candidates, including its highly selective Amylin peptide agonist.